Cargando…
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models
CD3 bispecific antibodies (bsAbs) show great promise as anticancer therapeutics. Here, we show in-depth mechanistic studies of a CD3 bsAb in solid cancer, using DuoBody-CD3x5T4. Cross-linking T cells with tumor cells expressing the oncofetal antigen 5T4 was required to induce cytotoxicity. Naive and...
Autores principales: | Kemper, Kristel, Gielen, Ellis, Boross, Peter, Houtkamp, Mischa, Plantinga, Theo S, de Poot, Stefanie AH, Burm, Saskia M, Janmaat, Maarten L, Koopman, Louise A, van den Brink, Edward N, Rademaker, Rik, Verzijl, Dennis, Engelberts, Patrick J, Satijn, David, Sasser, A Kate, Breij, Esther CW |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458754/ https://www.ncbi.nlm.nih.gov/pubmed/36271507 http://dx.doi.org/10.26508/lsa.202201481 |
Ejemplares similares
-
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
por: Muik, Alexander, et al.
Publicado: (2022) -
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
por: Engelberts, Patrick J., et al.
Publicado: (2020) -
Correction: DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
Publicado: (2022) -
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
por: Hiemstra, Ida H., et al.
Publicado: (2023) -
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
por: Muik, Alexander, et al.
Publicado: (2022)